Opella Healthcare, trading as Sanofi Consumer Healthcare, recently signed a dual partnership agreement with Alliance Healthcare and Phoenix Healthcare
Distribution for the wholesale supply of its consumer healthcare products to community pharmacies throughout the United Kingdom.
The new dual pharmacy wholesale partnership model, which became effective on 1 February 2024, underscores Sanofi's commitment to delivering exceptional customer
service to its customers, the company said in a press release.
The groundbreaking collaboration is expected to enhance operational efficiency as part of the company's go-to-market model, facilitating improved service levels
and stock availability of key products, including Cialis® Together, Allevia®, Buscopan®, Dulcolax®, and Phenergan, to community pharmacies in the UK.
Nick Linton, head of UK country operations, Sanofi Consumer Healthcare, said that the company is committed to supporting the "self-care agenda" in the UK.
"Making healthcare as simple as it should be to bring health and wellbeing to all is a key priority for us in 2024 and beyond," he commented.
Opella Healthcare, trading as Sanofi Consumer Healthcare, said it has entered into a dual partnership agreement with Alliance Healthcare and Phoenix
Healthcare Distribution for the wholesale supply of its products to UK pharmacies.
In effect from the start of February, the new dual partnership will ensure Sanofi Consumer Healthcare 'continues to provide its customers with exceptional
customer service', the company said, adding that the increased efficiency will facilitate improved service levels and stock availability of Cialis Together,
Allevia, Buscopan, Dulcolax and Phenergan to community pharmacies in the UK.
"At Sanofi Consumer Healthcare we are committed to supporting the self-care agenda in the UK," Nick Linton, head of UK country operations, commented.
"Making healthcare as simple as it should be to bring health and wellbeing to all is a key priority for us in 2024 and beyond. Our new wholesale model reflects our
deep commitment to working as efficiently as possible in close partnership with pharmacists to shape a healthier future."
Bas Vorsteveld, who was made vice president and general manager for Great Britain & Ireland (GBI) in November last year, is joined by Monica Michalopoulou as GBI marketing director and Onyeka Anugwom as GBI commercial excellence director GSK Consumer Healthcare.
He took over from Jonathan Workman, who held the position from 2018, and has now moved into the role of Business Unit general manager for Northern Europe.
Vorsteveld, who has 15 years' industry experience, played at major part in the merger of Novartis and GSK consumer healthcare businesses. Most recently, he held
the role of VP & head of commercial excellence EMEA LATAM at GSK Consumer Healthcare, where he spearheaded international sustainability initiatives.
Commenting on his new role, Vorsteveld said: "I am incredibly honoured to have been a part of GSK Consumer Healthcare's journey to date and it is our collective ambition to deliver better everyday health with humanity for our customers, with a laser focus on 'self-care'.
"The recent pandemic has shown us that healthcare matters more now than ever before for our consumers. We want to redefine the role that self-care plays in people's lives, because it can bring long-term benefits for individuals and society, and is a key component of a sustainable healthcare system.
GSK Consumer Healthcare has recently unveiled a three-year programme to support the pharmacy profession with additional practical resources, mental health provisions and proposed policy changes as part of its new report Standing with Pharmacists in the Age of Self-Care.
The new report summarises findings from a roundtable hosted by GSK Consumer Healthcare in collaboration with the International Pharmaceutical Federation (FIP) earlier this year, which convened the pharmacy community, policy experts, and industry leaders to discuss the critical role of pharmacy in the age of self-care following the Covid-19 pandemic.
"We've seen Covid-19 have a significant impact on consumers' understanding of self-care, leading to an increased focus on wellbeing and everyday healthcare. During this time, pharmacies played a vital role in providing care and advice to their patients - particularly with many other health facilities closed. Our research shows that more than half of Europeans are planning to consult their pharmacist more often than before the pandemic. Yet in general, pharmacists remain under-utilised, despite being the most widely distributed health resource in Europe," said Tess Player, global head of expert at GSK Consumer Healthcare.
Global consumer healthcare company Haleon has launched a new centre of excellence for a global leader in consumer health which will bring together world leading
academics in human behaviour and frontline healthcare professionals including community pharmacists.
Unveiled at the International Pharmaceutical Federation (FIP) Congress in 'sunny' Seville, Spain on September 20, the Centre will operate as a community of healthcare
professionals and specialists in behavioural science, health psychology and the social sciences to solve some of the most pressing everyday health challenges.
Named the Centre for Human Sciences (CHS) the initiative will be the first major programme for healthcare professionals since the Haleon's launch on July 18 as an
independent, global leader in consumer health.
The Centre's mission is to support practising health professionals - pharmacists, pharmacy assistants and dental professionals - in serving their patients and
communities. Combining science with deep human understanding, CHS will bring expertise in physiology together with human sciences to deliver real world-solutions
and tangible interventions, resulting in measurable improvements in health outcomes through sustained behavioural change.
The Centre is facilitated by Robert Horne, professor of Behavioural Medicine at UCL School of Pharmacy, who started his career as a practising pharmacist but later
chose to become a behavioural scientist when he saw an opportunity to address issues around psycho-social factors that acted as a hindrance in pharmacy practice.
Speaking to me in an exclusive three-way conversation alongside Tess Player, the global head of healthcare professional & health influencer marketing at Haleon, on
the sidelines of the FIP Congress 2022, Prof Horne expanded on what the Centre was all about and how it would work.
"We've got some good ideas, but it's not a pre-filled prescription that we're going to deliver at scale from the start. What Haleon is t
Consumer goods giant Unilever signalled on Monday (January 17) it would pursue a deal for GlaxoSmithKline's consumer healthcare business, calling it a "strong strategic fit" after its £50 billion offer was refused.
GSK confirmed on Saturday that it had rejected three approaches from the Dove-soap maker, adding it intended to stick to its own plan to spin off the business as a separate company later this year.
"GSK Consumer Healthcare would be a strong strategic fit," Unilever said in a statement as it unveiled a strategy update in the wake of the weekend's takeover news.
Unilever said it was "committed to accelerating the company's growth and repositioning the portfolio into higher growth categories.
"As a result of the reporting of Unilever's interest in GSK Consumer Healthcare, we are today bringing forward a planned update, setting out the strategic direction that the company is pursuing," Unilever said.
US pharmaceutical giant Johnson & Johnson on Friday (November 12) announced plans to break up into two listed companies, separating its consumer health arm that sells Band-Aids and Tylenol from its pharmaceutical division.
Johnson & Johnson said in a statement it will create "two global leaders that are better positioned to deliver improved health outcomes for patients and consumers through innovation."
It plans to complete the separation in 18-24 months, creating two publicly traded companies. CEO Alex Gorsky said the decision was made following a "comprehensive
review."
The board and management believe the split is "the best way to accelerate our efforts to serve patients, consumers, and healthcare professionals, create opportunities
for our talented global team, drive profitable growth, and -- most importantly -improve healthcare outcomes for people around the world," he said.
US drugs giant Pfizer will exit its consumer healthcare joint venture with GlaxoSmithKline after the unit is spun off next month, the British drugmaker
said Wednesday (June 1).
GSK will list the healthcare division on the London stock market on July 18 as it looks to concentrate on the pharmaceutical business, it said in a statement.
The London-listed firm currently owns a majority 68 percent of the unit, with Pfizer holding the remainder.
"Pfizer intends to exit its 32-percent ownership interest in Haleon in a disciplined manner, with the objective of maximising value for Pfizer shareholders," GSK
said.
Covid jab maker Pfizer is seeking to pursue its focus on "innovative medicines and vaccines", it noted.
The unit, which will be named Haleon after the demerger, makes products including Sensodyne toothpaste, pain relief drug Panadol and cold treatment Theraflu.
Consumer healthcare group Haleon on Thursday announced that it has entered into a binding agreement for the sale of the ChapStick brand to Suave Brands
Company, a company owned by American private equity firm Yellow Wood Partners.
The British consumer healthcare company has agreed to sell its lip balm brand to Suave for about $430 million in cash and a minority interest in the buyer,
valued at around $80 million.
Haleon, which was spun off from the GSK Group in July 2022, said that cash proceeds from the sale would be used to pay down debt.
ChapStick generated £112 million ($142.5 million) in revenue in 2023, said Haleon, adding that the sale is likely to close in the second quarter of 2024.
Brian McNamara, Chief Executive Officer, Haleon, said: "Today's announcement is consistent with Haleon being proactive in managing our portfolio, and being
rigorous and disciplined where there are opportunities for divestment.
"While ChapStick is a great brand, much loved by consumers around the world, it is not a core focus for Haleon.
In a long scripted overhaul of its business, GlaxoSmithKline spun off its consumer health business on Monday (July 18) in the biggest listing in Europe for
more than a decade.
The new company, Haleon, becomes the world's biggest standalone consumer health business, home to brands including Sensodyne toothpaste, pain relief drug Panadol
and cold treatment Theraflu.
Shares in Haleon started trading at 330 pence on Monday morning, giving the business a market valuation of around £30.5 billion - dashing high hopes for Haleon's
much higher market valuation after GSK in January said it had rebuffed a £50 billion offer from Unilever on the basis it was too low.
The major strategy shift by GSK chief executive Emma Walmsley to focus on the company's core pharmaceuticals business comes after she faced intense activist
shareholder pressure over its delays in producing Covid jabs and treatments.
STADA has appointment Nigel Stephenson as General Manager UK with effect from 1 August 2023.
Based in Huddersfield, UK, Stephenson will report directly to STADA's Head of Western Europe and Germany, Stephan Eder.
He will take over from Rudolf Bär, who has successfully led the UK business for almost one year in addition to his responsibilities for STADA's Mid-Sized European
Markets.|
A dynamic and modern commercial leader with extensive experience in sales and marketing across Western, Central and Eastern Europe, and the UK in leading
pharmaceutical, consumer healthcare and fast-moving consumer goods companies.
He joins STADA from consumer healthcare leader Haleon, where he most recently served as General Manager Switzerland.
"With his strong people and results orientation, along with deep purpose-driven engagement, Nigel will support our UK team in realizing its full potential
through innovative and inclusive leadership," stated Eder.
Over the last few years, we've seen the aftermath of Covid-19, with the demand for consumer health products being unprecedented and unpredictable, placing
pressure on supply chains and labour market. In turn, the industry has experienced acute shortages across the healthcare sector, placing huge pressure on
pharmacists, doctors, nurses, and other healthcare professionals.
Europe has an estimated shortage of around 50,000 public-sector doctors[1], which is set to increase in the coming years. While this shortage stems from several
complex problems, there is a hidden force that could play a key part in helping to alleviate this burden. That force is the potential of self-care.
Encouragingly, last month the UK government recognised the unique role that self-care can play through the introduction of its Delivery plan for recovering access
to primary care. Through this, it has pledged to empower patients to manage their own health through several commitments, including improving accessibility to
online tools and reclassifying medicines to make formerly prescribed options available over the counter.
Thornton & Ross is all set to expand its consumer healthcare offering by acquiring the well-established Opticrom eye-drops brand from Sanofi in the UK.
Opticrom forms part of a wider transaction between Thornton & Ross' parent group, STADA, and Sanofi for eight local consumer healthcare brands across several
countries, including Belgium, Germany, Hungary, Spain and the UK. The transaction will be financed with a combination of cash on balance sheet and existing
facilities, and is scheduled to close in the fourth quarter of 2023, subject to customary approvals of relevant regulatory authorities.
Opticrom Allergy 10ml bottle and 20 single doses for itchy, watery, red and inflamed eyes can be found behind the pharmacy counter, while Opticrom Hayfever
10ml bottle is available to purchase via self-selection to soothe and relieve eye symptoms of hayfever.
These non-prescription medicines contain 20 mg/1ml sodium cromoglicate (2.0% w/v) and offer relief within 2 minutes.
Holland & Barrett, the UK's leading wellness retailer, has become the latest retailer regulatory member of PAGB, the consumer healthcare association.
PAGB represents the manufacturers of branded over-the-counter (OTC) medicines, self care medical devices and food supplements in the UK.
Holland & Barrett's decision to PAGB follows its recent introduction of a selected range of OTC and healthcare products in its stores across the UK. These
include painkillers, cough and cold medicines, children's health essentials, hay fever relief, as well as skin and gastrointestinal products.
With this expansion, the retailer aims to not only help customers to stay well, but also provide relief when needed.
British pharmaceutical giant GlaxoSmithKline beat first-quarter sales and earnings forecasts on Wednesday (April 27), helped by demand for its Covid-19 therapy
and shingles vaccine, as the company moves towards the July separation of its consumer health business.
Profit after tax jumped 68 percent to £1.8 billion ($2.3 billion, 2.1 billion euros) compared with the start of 2021.
Sales climbed 32 percent to almost £9.8 billion.
"We have delivered strong first-quarter results in this landmark year for GSK, as we separate consumer healthcare and start a new period of sustained growth," chief
executive Emma Walmsley said in the earnings statement.
"Our results reflect further good momentum across speciality medicines and vaccines, including the return to strong sales growth for Shingrix and continuing pipeline progress."
The shingles vaccine generated £698 million in quarterly sales, beating analyst estimates of 528 million.
Walmsley is seeking to reshape GSK after facing fierce investor criticism over the company's delay in producing Covid jabs and treatments.
Jeremy Meader has resigned as managing director of Numark after five years on the job, and having lead the wider PHOENIX group's sales and marketing teams for
about eight years.
A press release issued on Wednesday (February 1) said Mr Meader "has decided to leave the business to pursue his career outside of the PHOENIX group", the owner of
Numark.
It said: "PHOENIX thanks Jeremy for his commitment and dedication over the years and wishes him all the best for his professional and private future."
Previous to joining PHOENIX, Mr Meader was head of sales at Alliance Healthcare, a role he took up in 2012 after serving GSK's Consumer Healthcare division for over
13 years in various capacity.
Rowlands Pharmacy has joined hands with healthcare software company HasHealth for an enhanced digital proposition to facilitate seamless delivery of a raft of
clinical services including flu and travel vaccinations.
The new system is now available across 400 Rowlands pharmacies across the UK.
The partnership comes as Rowlands Pharmacy strives to provide patients with a seamless booking experience whilst minimising time-consuming administration for pharmacy
staff, with its waiting list, medical pre-screen questionnaires and resource management capabilities, the company said in a statement.
HasHealth offers a virtual healthcare software solution that allows community pharmacies to schedule, manage, and communicate with patients easily online. It combines
its cutting-edge video technology with booking and management software, which can be adapted to any clinical service.
Nigel Swift, managing director at Rowlands Pharmacy, commented: "We pride ourselves on listening to our staff, based on feedback we knew we could do better with our
digital proposition for clinical services and flu vaccinations in particular.
Many of us know that oral health plays a hugely important role in our general health and wellbeing. We're continuing to see a rise of cosmetic dentistry
such as veneers and teeth whitening[1] but fundamentally, it shouldn't be forgotten that oral health encompasses so much more than aesthetics. Our diets,
the oral hygiene products we are using, and our brushing techniques are all elements that impact our oral health.
It's been hard to miss in the news that there is a dental crisis in the UK, with 'dental deserts' leaving some areas with over 3,000 patients for every NHS
dentist[2]. With oral health being of such importance to our overall health[3], it's only reiterated to us at Haleon that we must continue to promote access
to dental care and understanding of better dental health.
As I've mentioned in previous articles for Pharmacy Business, an understanding of preventative, self-care is hugely beneficial, not just to improve health
inclusivity but to help reduce these current burdens on both healthcare and dentistry professionals. We know that at Haleon, we, and the consumer healthcare
industry as a whole, have a responsibility to empower people to equip themselves with the tools and information to participate in their own and loved ones'
health - and dental health is such an important part of that.
Proprietary Association of Great Britain, PAGB - which represents manufacturers of branded over-the-counter (OTC) medicines, self-care medical devices
and food supplements - on Tuesday (12 December) celebrated 40 years of reclassification of medicines.
Expanding self-care for common ailments and minor injuries will not only help ease pressure on primary care services, but also provides significant potential
savings for the NHS, the consumer healthcare association highlighted during the event.
Nurofen (ibuprofen) and Imodium (loperamide) were the first medicines to go through Medicines and Healthcare products Regulatory Agency (MHRA)'s switch process
in 1983 to make them available over the counter - OTC.
Other reclassified medicines which were once available on prescription only include Voltarol (diclofenac dimethylammonium), Canesten (clotrimazole), Nexium
(esomeprazole), Nicorette, Nicotinell and Niquitin (nicotine replacement therapies), Regaine (minoxidil), Viagra Connect (sildenafil), Cialis Together
(tadalafil) for erectile dysfunction and Gina (estradiol hemihydrate) for the treatment of postmenopausal symptoms such as vaginal dryness.
UK-based consumer health company Kenvue has developed a series of tools and materials to support healthcare professionals - including pharmacy teams - with
their conversations with smokers on their quit journey.
This is part of their newly launched Smokefree Families initiative, which aims to help reduce the number of smoking households with children in England.
Kenvue believes that pharmacists and their teams are vital to the success of this initiative, as they play a crucial role in supporting smokers in their quit
journey.
"As trusted sources of support and advice to families across the country, we firmly believe that community pharmacy teams are crucial to the success of our Smokefree
Families initiative," Manoj Raghunandanan, Area Managing Director, Northern Europe at Kenvue, told Pharmacy Business.
"To support them, we've created a series of tools and materials that can help pharmacists and other healthcare professionals tackle sensitive conversations with
new and expectant parents, their partners and support networks, and ultimately motivate them on their quit journey."